this must be archive.php

Deferasirox + EPO study

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: All.
  2. SEVERITY OF MDS: Low to Intermediate 1
  3. NAME OF DRUG: Deferasirox and Erythropoietin (EPO)
  4. Aims and benefits: This trial will assess the impact on hemoglobin, platelets and neutrophil, and iron levels in patients treated with Deferasirox combined with Erythropoietin (compared to Erythropoietin alone)

Read More


MONOCLE

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

MONOCLE IS NOW CLOSED TO RECRUITMENT

The trial was unable to demonstrate that Tefinostat had any effect in modifying CMML

    1. SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
    2. SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
    3. NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.

Read More


CATAPULT

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: MDS with 10% bone marrow blasts and also Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Gene modified WT1 (Wilms’ Tumor 1) TCR therapy - Patient's white blood cells (T cells) will be modified by transferring a gene which enables them to make a new T cell receptor (TCR) that can recognize fragments of a protein called WT1 which is present at abnormally high levels on the surface of myelodysplastic and leukaemic cells.

Read More


VIOLA – Azacitidine and Lenalidomide Salvage Therapy

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: Relapsed MDS after undergoing an Allogeneic Stem Cell Transplantation); also for Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: All
  3. NAME OF DRUG: Azacitidine and Lenalidomide

Read More


REDDS

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

REDDS IS NOW CLOSED TO RECRUITMENT

Following this study the investigators now have the information needed to progress to a definitive trial of different red cell transfusion strategies to determine effectiveness and safety.

  1. SUB-TYPE OF MDS: All MDS patients who are transfusion dependant
  2. SEVERITY OF MDS: All
  3. INVESTIGATIONAL INTERVENTION: Blood transfusion support

Read More


FIGARO

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: Patients with AML and MDS undergoing reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT)
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Novel conditioning regimen: fludarabine/cytarabine/amsacrine/busulphan/ATG (FLAMSA-BU)

Read More


MEDALIST (HAEM 5606)

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

MEDALIST IS NOW CLOSED TO RECRUITMENT

Treatment with Luspatercept resulted in a significantly reduced transfusion burden compared with placebo. Regulatory submissions planned in the United States and Europe in the first half of 2019.

    1. SUB-TYPE OF MDS: IPSS-R and ring sideroblasts
    2. SEVERITY OF MDS: Low or Intermediate
    3. NAME OF DRUG: Luspatercept, a protein found to promote red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin.

Read More


KHK2823 in Patients with AML and MDS

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: All types - see specific inclusion criteria
  2. SEVERITY OF MDS: Low Risk or High Risk
  3. NAME OF DRUG: KHK2823

Read More


Durvalumab in Previously Untreated Patients

*CLOSED TO RECRUITMENT*

  1. SUB-TYPE OF MDS: Higher risk MDS and also elderly patients (age ≥ 65 years) with Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: Intermediate –2 or High Risk
  3. NAME OF DRUG: Subcutaneous Azacitidine and Durvalumab, which activates the immune system to have a response against tumor cells.

Read More


CAMELLIA

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

CAMELLIA

    1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukemia that has returned after a period of improvement (relapsed) or have not responded to previous treatment (refractory).
    2. SEVERITY OF MDS: Higher Risk
    3. NAME OF DRUG: Anti-CD47 monoclonal antibody, Hu5F9-G4 (target therapy that blocks the growth of cancer cells)

Read More


Free donations by shopping